What is the Origin of Aromatase Inhibitor Discontinuation?

This concept is derived from oncology and endocrinology, specifically within the context of adjuvant endocrine therapy protocols for breast cancer management. The practice acknowledges the balance between long-term efficacy in preventing recurrence and the necessity of managing significant side effects that impair quality of life.

What is the Mechanism of Aromatase Inhibitor Discontinuation?

Aromatase inhibitors suppress the peripheral conversion of androgens into estrogen, effectively lowering circulating estrogen levels to inhibit the growth of hormone-sensitive tumors. Upon discontinuation, the body's peripheral aromatase activity resumes, potentially leading to a gradual or rapid increase in estrogen levels, which can influence tumor dormancy or cause a shift in the patient's hormonal milieu. Clinicians must assess bone mineral density, lipid profiles, and menopausal symptoms following this change, often considering alternative strategies for bone and cardiovascular protection.

Aromatase Inhibitor Discontinuation

Meaning

Aromatase Inhibitor Discontinuation refers to the cessation of therapeutic use of medications that block the enzyme aromatase, which is primarily used in postmenopausal women to treat hormone-receptor-positive breast cancer by reducing systemic estrogen production. This clinical decision marks the end of a planned course of adjuvant therapy or an early stoppage due to drug-related toxicity or patient preference. The discontinuation phase requires careful clinical management to monitor for potential recurrence and address residual or rebound symptoms.